Comparison of patients enrolled in RODIN and the remainder of the cohort
| . | UK-RODIN subjects (n = 88) . | Non-RODIN subjects (n = 319) . | P . |
|---|---|---|---|
| Inhibitors reported, n (%) | |||
| All | 33 (37.5) | 85 (26.7) | .05 |
| High titer | 17 (19.3) | 43 (13.5) | .17 |
| Low titer | 16 (18.2) | 42 (13.2) | .23 |
| Age at first treatment, mo | |||
| Median | 8 | 9 | |
| IQR | 2-12 | 4-14 | .14 |
| Range | 0-52 | 0-95 | |
| Ethnicity | |||
| White | 73 (83) | 281 (88) | .21 |
| Nonwhite | 15 (17) | 38 (12) | |
| FVIII mutation | |||
| High risk | 54 (61.4) | 190 (59.6) | |
| Low risk | 31 (35.2) | 102 (32) | .79 |
| Not known | 3 (3.4) | 27 (8) | |
| Intensive treatment at first exposure, n (%) | |||
| Yes | 19 (21.6) | 37 (11.6) | .02 |
| No | 69 (78.4) | 274 (85.9) | |
| Not known | 0 (0.0) | 8 (2.5) | |
| Intensive treatment during first 50 EDs (excluding first exposure), n (%) | |||
| Yes | 40 (45.5) | 135 (42.3) | .82 |
| No | 48 (54.5) | 171 (53.6) | |
| Not known | 0 (0.0) | 13 (4.1) | |
| FH of a FVIII inhibitor | 15 (17.05) | 26 (8.15) | .03 |
| Peak inhibitor titer | |||
| Median | 5 | 5 | |
| IQR | 2. 0-29.2 | 1.13-17.9 | .86 |
| Range | 0.07-222 | 0.3-1562 | |
| EDs to inhibitor formation | |||
| Median | 16.5 | 15 | |
| IQR | 8.75-31.75 | (9-29) | .93 |
| Range | 3-358 | [1-442] | |
| Follow up for patients not developing an inhibitor, mo | |||
| Median | 48.0 | 44.3 | |
| IQR | 30.0-69.0 | 24.0-60.0 | .58 |
| Range | 6.0-142.5 | 1.6-154.5 |
| . | UK-RODIN subjects (n = 88) . | Non-RODIN subjects (n = 319) . | P . |
|---|---|---|---|
| Inhibitors reported, n (%) | |||
| All | 33 (37.5) | 85 (26.7) | .05 |
| High titer | 17 (19.3) | 43 (13.5) | .17 |
| Low titer | 16 (18.2) | 42 (13.2) | .23 |
| Age at first treatment, mo | |||
| Median | 8 | 9 | |
| IQR | 2-12 | 4-14 | .14 |
| Range | 0-52 | 0-95 | |
| Ethnicity | |||
| White | 73 (83) | 281 (88) | .21 |
| Nonwhite | 15 (17) | 38 (12) | |
| FVIII mutation | |||
| High risk | 54 (61.4) | 190 (59.6) | |
| Low risk | 31 (35.2) | 102 (32) | .79 |
| Not known | 3 (3.4) | 27 (8) | |
| Intensive treatment at first exposure, n (%) | |||
| Yes | 19 (21.6) | 37 (11.6) | .02 |
| No | 69 (78.4) | 274 (85.9) | |
| Not known | 0 (0.0) | 8 (2.5) | |
| Intensive treatment during first 50 EDs (excluding first exposure), n (%) | |||
| Yes | 40 (45.5) | 135 (42.3) | .82 |
| No | 48 (54.5) | 171 (53.6) | |
| Not known | 0 (0.0) | 13 (4.1) | |
| FH of a FVIII inhibitor | 15 (17.05) | 26 (8.15) | .03 |
| Peak inhibitor titer | |||
| Median | 5 | 5 | |
| IQR | 2. 0-29.2 | 1.13-17.9 | .86 |
| Range | 0.07-222 | 0.3-1562 | |
| EDs to inhibitor formation | |||
| Median | 16.5 | 15 | |
| IQR | 8.75-31.75 | (9-29) | .93 |
| Range | 3-358 | [1-442] | |
| Follow up for patients not developing an inhibitor, mo | |||
| Median | 48.0 | 44.3 | |
| IQR | 30.0-69.0 | 24.0-60.0 | .58 |
| Range | 6.0-142.5 | 1.6-154.5 |